EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Li–Fraumeni‐associated osteosarcomas: The French experience

Emilie Saucier, Gaëlle Bougeard iD, Anne Gomez-Mascard, Catherine Schramm, Rachid Abbas iD, Pablo Berlanga iD, Claire Briandet, Marie-Pierre Castex, Nadège Corradini, Carole Coze, Léa Guerrini-Rousseau, Jean-Marc Guinebretière und 12 weitere

Pediatric Blood & Cancer · 2024-12 · 71 (12)

DOI: 10.1002/pbc.31362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 10.10.2024. Verfasst von Emilie Saucier und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Children and Adolescents Oncology, Gustave Roussy Cancer, Paris-Saclay University, Villejuif, France. Hauptthemen laut MEDLINE: Osteosarcoma, Li-Fraumeni Syndrome, Bone Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Describe clinical characteristics and outcome of Li–Fraumeni syndrome (LFS)‐associated osteosarcomas.

Methods

TP53 germline pathogenic/likely pathogenic variant carriers diagnosed with osteosarcoma in France between 1980 and 2019 were identified via the French Li–Fraumeni database at Rouen University Hospital. Sixty‐five osteosarcomas in 52 patients with available clinical and histological data were included. The main clinical characteristics were compared with data from National Cancer Institute's SEER (Surveillance, Epidemiology, and End Results) for patients of the same age group.

Results

Median age at first osteosarcoma diagnosis was 13.7 years (range: 5.9–36.7). Compared to unselected osteosarcomas, LFS‐associated osteosarcomas occurred more frequently in patients less than 10 years of age (23% vs. 9%), and when compared with osteosarcomas in patients less than 25 years were characterized by an excess of axial (16% vs. 10%) and jaw sites (15% vs. 3%) and histology with predominant chondroblastic component and periosteal subtypes (17% vs. 1%). Metastases incidence (25%) was as expected in osteosarcomas. After the first osteosarcoma treatment, the rate of good histologic response (62%) and the 5‐year progression‐free survival (55%, 95% confidence interval [CI]: 42.6−71.1) were as expected in unselected series of osteosarcomas, whereas the 5‐year event‐free survival was 36.5% [95% CI: 25.3−52.7] due to the high incidence of second malignancies reaching a 10‐year cumulative risk of 43.4% [95% CI: 28.5−57.5].

Conclusion

In osteosarcoma, young age at diagnosis, axial and jaw sites, histology with periosteal or chondroblastic subtype, and synchronous multifocal tumors should prompt suspicion of a germline TP53 mutation. Standard treatments are effective, but multiple malignancies impair prognosis. Early recognition of these patients is crucial for tailored therapy and follow‐up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaLi-Fraumeni SyndromeBone NeoplasmsHumansFemaleMaleAdolescentChildAdultFranceYoung AdultChild, PreschoolGerm-Line MutationSurvival RatePrognosisTumor Suppressor Protein p53Follow-Up Studies

Stichwörter der Autor:innen

Li–Fraumeni syndromeTP53 variantschondroblastic osteosarcomajaw osteosarcomaosteosarcomaosteosarcomatosisperiosteal osteosarcomapredisposition

Substanzen

TP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Children and Adolescents Oncology, Gustave Roussy Cancer, Paris-Saclay University, Villejuif, France.
  • Univ Rouen Normandie, Inserm U1245, Normandie Univ, CHU Rouen, Department of Genetics, Rouen, France.
  • Department of Pathology, CHU, IUCT-Oncopole, University of Toulouse, Eq19. ONCOSARC CRCT, UMR 1037 Inserm/UT3, ERL 5294 CNRS, Toulouse, France.
  • Department of Biostatistics and Epidemiology, Gustave Roussy, Paris-Saclay University, Villejuif, France.
  • Inserm, Clinical Trial Unit 1418 (CIC1418) Clinical Epidemiology, Paris, France.
  • Department of Pediatric Haematology-Oncology, Dijon University Hospital, Dijon, France.

ORCID-Profile: Gaëlle Bougeard, Rachid Abbas, Pablo Berlanga, Pierre Khneisser, Cyril Lervat, Laurence Brugieres

Zitieren

APA

Saucier, E., Bougeard, G., Gomez-Mascard, A., Schramm, C., Abbas, R., Berlanga, P., Briandet, C., Castex, M. P., Corradini, N., Coze, C., Guerrini-Rousseau, L., Guinebretière, J. M., Khneisser, P., Lervat, C., Mansuy, L., Marec-Berard, P., Marie-Cardine, A., Mascard, E., Saumet, L., …, & Brugieres, L. (2024). Li–Fraumeni‐associated osteosarcomas: The French experience. Pediatric Blood & Cancer, 71(12). https://doi.org/10.1002/pbc.31362

Vancouver

Saucier E, Bougeard G, Gomez-Mascard A, Schramm C, Abbas R, Berlanga P, et al. Li–Fraumeni‐associated osteosarcomas: The French experience. Pediatric Blood & Cancer. 2024;71(12). doi:10.1002/pbc.31362

BibTeX
@article{Saucier2024,
  author = {Saucier, Emilie and Bougeard, Gaëlle and Gomez-Mascard, Anne and Schramm, Catherine and Abbas, Rachid and Berlanga, Pablo and Briandet, Claire and Castex, Marie-Pierre and Corradini, Nadège and Coze, Carole and Guerrini-Rousseau, Léa and Guinebretière, Jean-Marc and Khneisser, Pierre and Lervat, Cyril and Mansuy, Ludovic and Marec-Berard, Perrine and Marie-Cardine, Aude and Mascard, Eric and Saumet, Laure and Tabone, Marie-Dominique and Winter, Sarah and Frebourg, Thierry and Gaspar, Nathalie and Brugieres, Laurence},
  title = {Li–Fraumeni‐associated osteosarcomas: The French experience},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  volume = {71},
  number = {12},
  doi = {10.1002/pbc.31362}
}
Kostenlos starten →